Interferon and Genital Warts
- 14 October 1988
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 260 (14) , 2066
- https://doi.org/10.1001/jama.1988.03410140078026
Abstract
To the Editor.— The editorial by Dr Kirby1entitled "Interferon and Genital Warts: Much Potential, Modest Progress," leaves untouched some recent developments in the use of interferon for treatment of genital papillomavirus infections. We have found that low doses of recombinant interferon alpha 2a (Hoffmann-La Roche, Basle, Switzerland) or recombinant interferon alpha 2c (Thomae/Boehringer-Ingelheim, Federal Republic of Germany) (1 × 106to 5×.106U/d, subcutaneously) are equally potent, and perhaps even more potent, than high-dose treatment (18 × 106U/d) and that they cause fewer side effects.2,3In addition, when administered cyclically (for seven days followed by a therapy-free interval of four weeks, repeated approximately three times), low-dose interferon is highly effective with only minimal side effects.3With cyclic treatment, neutralizing antibodies against interferon are only rarely observed (one of 23 patients with genital warts treated with recombinant interferon alpha 2a had such antibodiesKeywords
This publication has 1 reference indexed in Scilit:
- The Effect of Asymptomatic Infection with HTLV-III on the Response of Anogenital Warts to Intralesional Treatment with Recombinant 2 InterferonThe Journal of Infectious Diseases, 1986